Stock Price Quote

ANUH PHARMA LTD.

NSE : ANUHPHRBSE : 506260ISIN CODE : INE489G01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE78.73-0.58 (-0.73 %)
PREV CLOSE ( ) 79.31
OPEN PRICE ( ) 79.64
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3004
TODAY'S LOW / HIGH ( )78.73 80.04
52 WK LOW / HIGH ( )74.03 121
NSE79.570.45 (+0.57 %)
PREV CLOSE( ) 79.12
OPEN PRICE ( ) 79.00
BID PRICE (QTY) 79.57 (15)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 23884
TODAY'S LOW / HIGH( ) 79.00 80.69
52 WK LOW / HIGH ( )74.25 122.85
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1960
Management Info
Arun Todarwal - Chairman - Managing Director
Registered Office

Address 3 - A, Shivsasgar Estate, North Wing,Dr. Annie Basant Road,Worli,
Mumbai,
Maharashtra-400018

Phone 022-66227575

Email anuh@sk1932.com

Website www.anuhpharma.com

Registrars Details
Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : BSE, NSE

NEWS

05Dec Anuh Pharma gets CEP for Sulfadimethox
Anuh Pharma has been granted the Certificate of Suitability (CEP) from t..
05Dec Anuh Pharma surges on getting CEP for
Anuh Pharma is currently trading at Rs. 82.03, up by 2.87 points or 3.63..
05Dec Anuh Pharma informs about updates
Anuh Pharma has informed that the Company has been granted the Certifica..
10Oct Anuh Pharma informs about confirmatio
In accordance with Regulation 74 (5) of the SEBI (Depositories and Parti..
09Sep Anuh Pharma informs about press release
Anuh Pharma has informed that it enclosed Newspaper Publication regardin..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit76.1099999999999473.529999999998
Gross Profit 99.1899999999999 610.059999999998
Operating Profit 128.57703.639999999999
Net Sales 1858.836615.15

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Procter&Gamble Healt (BSE)
peergroup  5695.00 (1.05%)
M.Cap ( in Cr)9418.57
Haleos Labs (BSE)
peergroup  1385.00 (3.40%)
M.Cap ( in Cr)418.73
Ajanta Pharma (BSE)
peergroup  2658.00 (1.48%)
M.Cap ( in Cr)33097.95
Pfizer (BSE)
peergroup  5021.00 (0.77%)
M.Cap ( in Cr)23031.01
Venus Remedies (BSE)
peergroup  786.50 (5.00%)
M.Cap ( in Cr)1051.31

Shareholding Pattern

PROMOTERS 71.82%
NON-INSTITUTION 28.18%
FI/BANKS/INSURANCE 0%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%

About Anuh Pharma Ltd.

Anuh Pharma Ltd. was incorporated in the year 1960. Its today's share price is 78.73. Its current market capitalisation stands at Rs 796.38 Cr. In the latest quarter, company has reported Gross Sales of Rs. 6664.95 Cr and Total Income of Rs.6709.7 Cr. The company's management includes Harmanbhai Tulsibhai Patel, Mita Dixit, Pradeep Thakur, Siddharth Shah, Gaurav Shah, Ketan Shah, Samir Shah, Bharat Shah, Vivek Shah, Ritesh Shah, Bipin Shah, Arun Todarwal, Manan Jayesh Vadhan.

It is listed on the BSE with a BSE Code of 506260 , NSE with an NSE Symbol of ANUHPHR and ISIN of INE489G01022. It's Registered office is at 3 - A, Shivsasgar Estate, North Wing,Dr. Annie Basant Road,WorliMumbai-400018, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Jayantilal Thakkar & Co, S I MOGUL & CO., SI Mogul & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.